Christopher Logothetis
M.D. Anderson Cancer Center · UT MD Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Christopher Logothetis as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 18:37 UTC. Open this list on ClinicalTrials.gov
- N/ANCT05840484 · Comprehensive Monitoring of Men With Prostate Cancer Cared for by "Active SurveillanceM.D. Anderson Cancer Center · recruiting · Prostate Cancer · principal investigator
- Ph2NCT03279250 · Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate CancerM.D. Anderson Cancer Center · completed · Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8 · principal investigator
- Ph2NCT01946165 · Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and EnzalutamideM.D. Anderson Cancer Center · completed · Prostate Cancer · principal investigator
- Ph2NCT01786265 · Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate CancerM.D. Anderson Cancer Center · active not recruiting · Prostate Adenocarcinoma, Recurrent Prostate Carcinoma · principal investigator
- Ph1/Ph2NCT01163084 · Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate CancerNational Cancer Institute (NCI) · terminated · Prostate Adenocarcinoma, Stage IIA Prostate Cancer AJCC v7, Stage IIB Prostate Cancer AJCC v7 · principal investigator
- Ph2NCT01088529 · Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate CancerCougar Biotechnology, Inc. · completed · Prostate Cancer · principal investigator
- Ph1NCT00872157 · BMTP-11 in Patients With Castrate-Resistant Prostate Cancer With Bone MetsM.D. Anderson Cancer Center · completed · Prostate Cancer · principal investigator
- Ph1NCT00512668 · Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate CancerNational Cancer Institute (NCI) · terminated · Adenocarcinoma of the Prostate, Recurrent Prostate Cancer · principal investigator
- N/ANCT00490763 · Active Surveillance in Prostate CancerM.D. Anderson Cancer Center · completed · Prostate Cancer · principal investigator
- Ph2NCT00084825 · Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008M.D. Anderson Cancer Center · completed · Metastatic Cancer, Prostate Cancer · study chair
- Ph2NCT00080678 · Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone MetastasesM.D. Anderson Cancer Center · completed · Metastatic Cancer, Prostate Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 18:37 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- 11 Prostate CancerP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2019 to 2025 · $24,690 awarded in 2025Grant number is on one of their registry trials
- Administrative Supplement to MD Anderson Cancer Center Prostate Cancer SPOREP50CA140388 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2009 to 2022 · $664,838 awarded in 2022Same name and institution; not confirmed by an ID
- University of Texas SPORE in Prostate CancerP50CA090270 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2001 to 2007 · $350,000 awarded in 2007Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Phase I Studies of Targeted Anti-Cancer TherapiesU01CA062461 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI James C Yao · fiscal years 1994 to 2013Named on NCT01163084
- Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis (U01)U01CA062491 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI GLENN LIU · fiscal years 1994 to 2013Named on NCT01163084
- Lipidomics-based biomarkers for risk of progression in early prostate cancerR21CA223527 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI John Warren Davis, Timothy Charles Thompson · fiscal years 2018 to 2019Named on NCT00490763
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 18:37 UTC. The ranking covers the 200 most relevant of 109 PubMed records, and a shared surname and initials can bring in a namesake. All 109 on PubMed
- Abiraterone and increased survival in metastatic prostate cancer.N Engl J Med · 20113,643 citationsRCR 95.7
- Abiraterone in metastatic prostate cancer without previous chemotherapy.N Engl J Med · 20132,334 citationsRCR 67.7
- 1,256 citationsRCR 33.8
- 1,127 citationsRCR 30.7
- 1,126 citationsRCR 35.2
- 648 citationsRCR 18.9
- A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.J Clin Oncol · 1990508 citationsRCR 14.3
- CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.Proc Natl Acad Sci U S A · 2008473 citationsRCR 8.1
- Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.Clin Cancer Res · 2010397 citationsRCR 7.5
- Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.J Clin Oncol · 2004393 citationsRCR 7.9